Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Cost-effectiveness targeting CLL

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen-mismatched donors

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The Need for Hospitalization due to SARS-CoV-2 in Children: A Population-based Estimate

    Research output: Contribution to journalLetterpeer-review

  2. PREVALENCE OF SARS-COV-2-ANTIBODIES IN DANISH CHILDREN AND ADULTS

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. A qualitative study of adolescent cancer survivors perspectives on social support from healthy peers - A RESPECT study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Truncation of asparaginase treatment due to asparaginase-related toxicities or silent inactivation (SI) is common and may increase relapse risk in acute lymphoblastic leukemia (ALL). We investigated relapse risk following suboptimal asparaginase exposure among 1401 children aged 1 to 17 years, diagnosed with ALL between July 2008 and February 2016, treated according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 protocol (including extended asparaginase exposure [1000 IU/m2 intramuscularly weeks 5-33]). Patients were included with delayed entry at their last administered asparaginase treatment, or detection of SI, and followed until relapse, death, secondary malignancy, or end of follow-up (median, 5.71 years; interquartile range, 4.02-7.64). In a multiple Cox model comparing patients with (n = 358) and without (n = 1043) truncated asparaginase treatment due to clinical toxicity, the adjusted relapse-specific hazard ratio (HR; aHR) was 1.33 (95% confidence interval [CI], 0.86-2.06; P = .20). In a substudy including only patients with information on enzyme activity (n = 1115), the 7-year cumulative incidence of relapse for the 301 patients with truncation of asparaginase treatment or SI (157 hypersensitivity, 53 pancreatitis, 14 thrombosis, 31 other, 46 SI) was 11.1% (95% CI, 6.9-15.4) vs 6.7% (95% CI, 4.7-8.6) for the 814 remaining patients. The relapse-specific aHR was 1.69 (95% CI, 1.05-2.74, P=.03). The unadjusted bone marrow relapse-specific HR was 1.83 (95% CI, 1.07-3.14, P=.03) and 1.86 (95% CI, 0.90- 3.87, P=.095) for any central nervous system relapse. These results emphasize the importance of therapeutic drug monitoring and appropriate adjustment of asparaginase therapy when feasible. This trial was registered at www.clinicaltrials.gov as #NCT03987542.

Original languageEnglish
JournalBlood
Volume137
Issue number17
Pages (from-to)2373-2382
Number of pages10
ISSN0006-4971
DOIs
Publication statusPublished - 29 Apr 2021

ID: 61695792